Cite
HARVARD Citation
Richardson, P. et al. (2019). Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet oncology. 20 (6), pp. 781-794. [Online].